IDIA•globenewswire•
Idorsia’s JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
Summary
Allschwil, Switzerland – January 5, 2026 Idorsia Ltd (SIX: IDIA) announces that Health Canada has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.1 The recommended dose is 12.5 mg orally once daily. The dose can be increased to 25 mg once daily for patients tolerating the 12.5 mg dose and in need of tighter blood pressure (BP) control.1
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 5, 2026 by globenewswire